What is the purpose of this trial?
This is a multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of "definite NASH" with fibrosis (excluding cirrhosis) as determined by the central histopathologist. Upon successful screening, subjects will be randomized to receive either emricasan 50 mg BID or emricasan 5 mg BID or matching placebo BID
Ages: 18 years and older
Dates: 03/09/2017 - 09/30/2018
Last Updated: 03/24/2017
Study HIC#: 2000020013